About 2,609 pounds of fully cooked, ready-to-eat smoked turkey breast products sold by New Braunfels Smokehouse of New Braunfels, Texas, because they may be contaminated with the bacterium Listeria monocytogenes. The organism can cause serious and sometimes fatal infections in young children, frail or elderly people, or people with weakened immune systems.
The products subject to recall include:
-1-pound packages of New Braunfels Smokehouse Sliced Smoked Turkey with package code 2210 on the label.
-4- to 6-pound packages of New Braunfels Honey-Glazed Spiral Sliced Smokehouse Hickory Smoked Boneless Breast of Turkey with package code 2180.
-4- to 6-pound whole breast packages of Stegall Boneless Hickory Smoked Turkey Breast with package code 2210.
-4- to 6-pound whole breast packages of Stegall Spiral Sliced Hickory Smoked Turkey Breast with package code 2180 or 2210.
The turkey items were produced Aug. 4 and distributed nationwide. Consumers with questions about the recall should contact the company at 800-537-6932.
(Copyright 2010 by The Associated Press. All Rights Reserved.)
Research suggests CT scan screening might lead to needless worry, treatment in these cases
Finding may gain significance as legalization spreads across U.S., study author says
Some natural remedies may help you recover from the cold.
Whether you started an application already and got stuck along the way, or you want to give it another try, here are some tips to get you enrolled.
Experts call two new drugs for hepatitis C ''game changers" that they expect will dramatically improve treatment for many of the 3 million Americans with a chronic infection.
An advisory panel of medical experts on Monday voted to recommend that U.S. health regulators approve an experimental drug for ulcerative colitis and Crohn's disease developed by Takeda Pharmaceutical Co. The panel voted by wide margins that the benefits outweigh the risks of the biotech drug, vedolizumab, and advised the Food and Drug Administration to approve it for both ulcerative colitis and Crohn's disease in patients who have not been helped by prior therapies. The FDA typically follows the recommendations of its expert advisory panels, but is not obligated to do so.